Chang H, Ewert S M, Bookchin R M, Nagel R L
Blood. 1983 Apr;61(4):693-704.
Fifteen compounds reported to be inhibitors of gelation or sickling were studied by standard methods. These tests included (1) the determination of the solubility of deoxyhemoglobin S or Csat, (2) evaluation of sickling in whole SS blood at various pO2s, (3) measurement of the oxygen affinity of hemoglobin and blood, and (4) examination of red cell indices and morphology. Among the 4 noncovalent agents tested, butylurea was the most potent inhibitor of gelation and sickling in vitro; however, relatively high concentrations were required compared to the covalent agents. In the latter group, bis-(3,5 dibromosalicyl)-fumarate, nitrogen mustard, and dimethyladipimidate were especially effective inhibitors of gelation and/or sickling. All of these compounds require further development before they can be considered for clinical use.
采用标准方法研究了15种据报道可抑制凝胶化或镰变的化合物。这些试验包括:(1)测定脱氧血红蛋白S或饱和状态下的溶解度;(2)评估不同氧分压下全SS血液中的镰变情况;(3)测量血红蛋白和血液的氧亲和力;(4)检查红细胞指数和形态。在所测试的4种非共价试剂中,丁基脲是体外凝胶化和镰变的最有效抑制剂;然而,与共价试剂相比,需要相对较高的浓度。在后一组中,双(3,5-二溴水杨基)-富马酸酯、氮芥和二甲基己二亚胺是凝胶化和/或镰变的特别有效抑制剂。在考虑将这些化合物用于临床之前,所有这些化合物都需要进一步研发。